EGFR and colorectal carcinoma: Currently, medical oncologists test for molecular biomarkers and use the mutation status of the KRAS gene to select patients with advanced-stage CRC with wild-type KRAS for treatment with a monoclonal antibody targeting EGFR (Amado et al., 2008).